Goldwater Asks Supreme Court to Limit FDA’s Authority Over Stem Cell Treatments

Published on Goldwater Institute

The Goldwater Institute has submitted a Supreme Court brief challenging the FDA’s authority to regulate autologous stem cell therapies that involve removing, processing, and reinserting a patient’s own cells. The group argues that such treatments are medical practice, not drugs, and should fall under state regulation, not FDA oversight. The brief warns that broad FDA control could stifle innovation in individualized therapies. It also makes a constitutional case, saying that patients have a right to choose treatments involving their own cells.

Read the full article on Goldwater Institute:

👉 Goldwater Asks U.S. Supreme Court to Enforce Limits on FDA’s Authority over Stem Cell Treatments

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.